How much dividend does Allovir pay?
Over the past 12 months, Allovir paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Allovir is expected to pay a dividend of 0 USD.
Allovir Dividend 2024
Allovir Dividend
0 USD
Allovir Dividend yield
Ticker
ALVR
ISIN
US0198181036
WKN
A2QAMR
How much dividend does Allovir 2024 pay?
According to the latest status from November 2024, Allovir paid a total of 0 USD per share in dividends within the last 12 months. With the current Allovir price of 0.95 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.
| = |
Historical Allovir Dividends
A dividend is paid times per year. Last year, the payout months were and .
| Paydate | Dividend |
|---|
Is the Allovir Dividend Safe?
Allovir has been increasing the dividend for 0 years.
Over the past 6 years, Allovir has increased it by an annual 0 %.
Over a five-year period, the distribution increased by 0%.
Analysts expect a Dividend Cut of -100% for the current fiscal year.
Dividend Details
Understanding Allovir's Dividend Distributions
Allovir’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.
Year-to-Year Comparison
Examining Allovir's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.
Impact on Investments
Allovir's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.
Interpreting Dividend Fluctuations
Changes in Allovir’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.
Allovir Aktienanalyse
What does Allovir do?
Allovir Inc was founded in 2013 in Cambridge, Massachusetts and is a biopharmaceutical company specializing in the development and commercialization of cellular immunotherapies for viral infections. The idea behind the founding of Allovir was to develop a new generation of immunotherapies with the potential to treat virus-related diseases that were previously difficult to treat. Allovir's business model is based on the development and commercialization of cellular immunotherapies that rely on the patient's immune system to fight infections. The company focuses on two main areas: infectious diseases and cancer. Within these areas, Allovir focuses on the development of therapies for severe viral infections such as BK virus, cytomegalovirus (CMV), and adenovirus, as well as the development of therapies to combat cancer. Allovir's first product candidates are Viral Associated Diseases (VAD) cell therapies developed to treat infections caused by BK virus, CMV, and adenovirus. These therapies consist of virus-specific T cells that are extracted from the patient's blood, amplified and activated in the laboratory, and then reintroduced into the patient where they can directly attack and eliminate the virus. Another promising product that Allovir is currently developing is ALVR106, a cellular immunotherapy for the treatment of cancer. ALVR106 is a CAR-T cell therapy candidate that aims to target HER2-positive solid tumors. The active ingredient is based on certain T cells that have been modified to specifically recognize and attack tumor-specific antigens. Allovir has conducted several successful clinical trials in recent years and has achieved promising results. Significant progress was observed in a clinical trial for the treatment of BK virus infections in kidney transplant patients. Therapy with virus-specific T cells resulted in a significant reduction in viral load and improvement in kidney function. Allovir's therapy also showed promising results in a Phase 2 trial for the treatment of CMV in bone marrow transplant patients. Allovir has established a strong position in the field of cellular immunotherapies for viral infections in recent years. The company has built an impressive research and development platform and has an experienced team of researchers and developers. The clinical results of Allovir's products demonstrate a high potential for future developments, and the company is expected to continue to grow and innovate in the coming years. Allovir is one of the most popular companies on Eulerpool.com.Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Frequently Asked Questions about Allovir stock
What is the dividend yield of Allovir?
The current dividend yield of Allovir is .
When does Allovir pay dividends?
Allovir pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Allovir?
Allovir paid dividends every year for the past 0 years.
What is the dividend of Allovir?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Allovir located?
Allovir is assigned to the 'Health' sector.
Wann musste ich die Aktien von Allovir kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Allovir from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.
When did Allovir pay the last dividend?
The last dividend was paid out on 11/5/2024.
What was the dividend of Allovir in the year 2023?
In the year 2023, Allovir distributed 0 USD as dividends.
In which currency does Allovir pay out the dividend?
The dividends of Allovir are distributed in USD.
Andere Kennzahlen von Allovir
Our stock analysis for Allovir Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Allovir Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
